BioMarin Pharmaceutical’s (BMRN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $86.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 52.48% from the company’s current price.

BMRN has been the topic of a number of other research reports. Citigroup increased their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. HC Wainwright reaffirmed a “neutral” rating and set a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Royal Bank Of Canada cut their price target on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 7th. Canaccord Genuity Group increased their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, Jefferies Financial Group increased their price target on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.68.

BioMarin Pharmaceutical Trading Up 3.2%

BioMarin Pharmaceutical stock traded up $1.73 during trading on Tuesday, hitting $56.40. The company’s stock had a trading volume of 2,356,684 shares, compared to its average volume of 2,093,981. The stock has a market capitalization of $10.92 billion, a price-to-earnings ratio of 152.43, a P/E/G ratio of 0.38 and a beta of 0.22. The stock’s fifty day moving average is $62.73 and its 200 day moving average is $58.67. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The business’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities research analysts predict that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently made changes to their positions in the business. Amundi increased its position in shares of BioMarin Pharmaceutical by 37.8% in the second quarter. Amundi now owns 259,782 shares of the biotechnology company’s stock worth $14,865,000 after acquiring an additional 71,246 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $14,203,000. Bank of New York Mellon Corp acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $66,107,000. Public Employees Retirement System of Ohio acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $3,461,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter worth $39,312,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.